| Project/Area Number |
22790108
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
KAKUTA Hiroki 岡山大学, 大学院・医歯薬学総合研究科, 准教授 (80362961)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | ステロイド / 抗炎症 / 核内受容体 / レチノイド / RXR / パーシャルアゴニスト / 皮膚炎モデル / 創薬化学 / レチノイドX受容体 |
|---|
| Research Abstract |
Effective substitutes of steroidal anti-inflammatory agents for the treatment of allergies and inflammation are required. Thus, we aimed to create new non-steroidal anti-inflammatory agents by targeting retinoid x receptors. By structural development of NEt-3IB(6-[N-ethyl-N-(3-isobutoxy-4-isopropylphenyl) amino] nicotinic acid), a potent RXR agonist, several RXR partial agonists were found. Among them, NEt-4IB(6-[N-ethyl-N-(4-isobutoxy-3-isopropylphenyl) amino] nicotinic acid) was found as a new orally available RXR partial agonist. In addition, this compound showed potent anti-inflammatory activity against the TPA induced skin inflammation without significant side effects.
|
